Dear Editor, We read with interest the article on human papillomavirus (HPV) DNA testing for cervical cancer in Brazil, authored by Zeferino et al (Brazilian Association for the Lower Genital Tract Pathology and Colposcopy (ABPTGIC, in the Portuguese acronym), as well as the subsequent letter to the editor, by Dr de Alcantara Segura, and the authors' reply.
1, 2 We agree that detection of adenocarcinomas represents a significant challenge for cervical cancer screening programs. In the United States, squamous cancer rates have seen a decline since the introduction of the Pap smear and molecular testing, but adenocarcinoma rates have remained unchanged (►Fig. 1). Moreover, Australia, which arguably has a best in class vaccination and screening program, is reporting a steady increase in adenocarcinoma rates. 3 As Dr. de Alcantara Segura points out, cytology is an insensitive method for screening adenocarcinomas. This has also been shown to be the case in the US, where Katki et al 4 reported that 63% of adenocarcinomas showed normal cytology results. In addition, screening for adenocarcinoma precursors by HPV is clearly less sensitive than squamous cancer precursors, as evidenced by the lack of progress in reducing the adenocarcinoma incidence since the introduction of molecular testing in the 2000s (►Fig. 1). A review of the recently published literature has identified a number of potential causes for the apparent lack of HPV detection within cervical adenocarcinoma, including the following: (i) Historical use of the Hybrid Capture 2 (HC2) assay and an associated higher rate of HPV negative cervical adenocarcinoma cases reported 5, 6 ; (ii) low viral load of HPV and detection only with nested polymerase chain reaction (PCR) methods
7
; (iii) L1 vs E6/E7 detection (HPV integration and L1 deletion) 8, 9 ; (iv) non-HR HPV genotypes associated with some adenocarcinomas
10
; and (v) rare histological subtypes that either have low viral loads or are HPVnegative. 11, 12 There are some cervical adenocarcinoma tissues that appear to be non-HPV derived. Clear cell adenocarcinoma can arise from prenatal diethylstilbestrol exposure that are not believed to be associated with high-risk HPV infections. Likewise, gastric-type adenocarcinomas are considered to be either HPV-negative, or at least, have very low levels of HPV present.
13
In particular, target region selection has a significant impact on an HPV DNA test's ability to detect cancers. The majority of assays target the L1 region of the virus, and the gene is prone to deletion during virus integration as disease progresses.
14-16
Viral integration can also occur early in the disease process and is detected in routine liquid-based cytology specimens of precancer patients.
14,17 While it has long been reported that performed a comprehensive analysis in a cohort of over 1.2 million women with screening histories preceding cancers (n ¼ 623) and precancers (n ¼ 5369). They found that HPV testing identified more women subsequently diagnosed with cancer (P < 0.001) and precancer (P < 0.001), except for within 12 months when cytology showed improved cancer detection (P ¼ 0.10). However, this represented, at most, 5 cases per million women per year, and the authors questioned the utility of continued co-testing versus primary HPV screening -"Excessive screening in an attempt to prevent every case could have minimal cancer prevention benefits while increasing the harms of screening". The decision on which screening paradigm to adopt is often driven by both the science as well as regional or countryspecific parameters, including infrastructure, societal risk tolerance, and funding/reimbursement. However, it is important that clinicians and decision makers carefully weigh the safety and effectiveness of different approaches so as to maximize the impact of any screening program. Adenocarcinomas continue to represent a significant screening challenge, but it is hoped that with advancements in screening tools and the impact of vaccination, this performance gap will soon begin to close.
Finally, the issue with HPV-negative cervical adenocarcinoma poses both a challenge for cervical cancer screening programs and an important scientific and clinical question about the etiology of cervical glandular lesions. In our opinion, this situation necessitates a "call to arms" within the scientific and clinical community, in which a systematic investigation of cervical adenocarcinoma cases using deep nucleic acid sequencing analysis is warranted to answer the question about HPV association with all cervical adenocarcinomas. It is likely that these studies will lead to next generation cervical cancer screening technologies and improved adenocarcinoma detection.
Authors' Reply
Dear Editor, We are grateful for the insightful comments made by the authors and the well-structured review of literature, which indicates a new step on the debate of cervical cancer screening. The detection of adenocarcinomas represents a challenge for cervical cancer screening programs, and the performance of HPV tests on preventing them is debatable.
Even considering these issues, in regions where the incidence of cervical cancer is middle or high, the robust evidence about the DNA-HPV test performance supports the recommendations for implementing this technology instead of cytology, as long as accompanied by improvements on the programmatic strategy to ensure access and high coverage for the target population. It is clear that the benefits observed in the first stage of the HPV-DNA test implementation will be more evident in the control of squamous neoplasms. In the second stage, it is possible that the limitations pointed out in the detection of glandular neoplasia will be more evident. This debate is fairly current in countries with low rates of cervical cancer, which have already had controlled incidence rates.
In middle-income countries such as Brazil, where the incidence of squamous cell carcinoma is high, the impact of the implementation of HPV test-based screening surpasses the doubtful HPV test performance on detecting cervical adenocarcinoma. By now, it may only indicate a reduction in expectations regarding the impact to be observed with the new technique.
In the near future, new screening technologies might overcome these limitations. In addition, ongoing vaccination policies may contribute to reduce the impact of this issue. A more detailed analysis of the clinical and biomolecular characteristics of endocervical adenocarcinomas is quite opportune. Furthermore, a better understanding of such characteristics could provide new tools for screening test and strategies to improve adenocarcinoma detection.
Respectfully, Zeferino et al
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